ReviewDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2021
[Myopia treatment and prophylaxis with defocus incorporated multiple segments spectacle lenses].
Review in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Emerging Technologies for the Management and Mitigation of Myopia Progression: A Scoping Review.Health science reports · 2026Article
- Age, gender and regional/ethnic variations in emmetropic axial growth rate.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025Article
- Efficacy of Spectacle Correction Using Defocus Incorporated Multiple Segments in the Myopic Population.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Effect of defocus incorporated multiple segments (DIMS) spectacle lenses on myopia progression in children: a retrospective analysis in a German real-life clinical setting.BMC ophthalmology · 2024Article
- Age-matched analysis of axial length growth in myopic children wearing defocus incorporated multiple segments spectacle lenses.The British journal of ophthalmology · 2024Article
- A Comparison of Optical Biometers Used in Children for Myopia Control.Klinische Monatsblatter fur Augenheilkunde · 2023Article
- [Recommendations for progressive myopia in childhood and adolescence. Statement of the DOG, BVA and the Bielschowsky Society for Strabismus Research and Neuroophthalmology : Status June 2022].Die Ophthalmologie · 2023Review
- Safety of DIMS Spectacle Lenses and Atropine as Combination Therapy for Myopia Progression.Klinische Monatsblatter fur Augenheilkunde · 2022Article
- Eye growth of children undergoing myopia control treatment compared with emmetropic eye growth.Die Ophthalmologie · 2022Article
- [Eye growth of children undergoing myopia control treatment compared with emmetropic eye growth. German version].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2022Article
- Overview on Defocus Incorporated Multiple Segments Lenses: A Novel Perspective in Myopia Progression Management.Vision (Basel, Switzerland) · 2022Review
- Vision tests on spectacle lenses and contact lenses for optical myopia correction: a pilot study.BMJ open ophthalmology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Excessive axial eye growth in children and adolescents leads to progressive myopia and can result in severe ocular diseases in adulthood. Various strategies have already been developed to inhibit progression of myopia. The novel single vision lens presented in this article features the defocus incorporated multiple segments (DIMS) technology and adds an easy to use, noninvasive option to the portfolio of myopia treatment. Initial studies showed promising results with only a very low side effect profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.